Company / R&D Expense
Tyra Biosciences, Inc. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$80.1M
FY2024
5-year range
$7.2M / $80.1M
FY2020-FY2024
Trend
+28.1%
vs FY2023
Sector context
#157 of 210
Health Care
What the data says
Tyra Biosciences, Inc.'s r&d expense of $80M is lower than 75% of companies in the Health Care sector (FY2024). R&D Expense has increased for 4 consecutive years, from $7M in FY2020 to $80M in FY2024.
Based on SEC 10-K filings.
$80M in FY2024 with a 3-year CAGR of +57.1%.
Improved from $43M to $80M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +57.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 25% in Health CareTop 75% of 210This company $80.1M Sector average $644.1M
▼
-87.6% below sector average
Key checks
Key Insights
- Tyra Biosciences, Inc.'s r&d expense has grown for 4 consecutive years.
- 3-year CAGR of +57.1%, indicating consistent growth.
- In FY2024, r&d expense increased 28.1% year-over-year.
- Ranks #157 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.83 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $80.1M | +28.1% |
| FY2023 | $62.5M | +45.4% |
| FY2022 | $43.0M | +108.4% |
| FY2021 | $20.6M | +186.5% |
| FY2020 | $7.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026